These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26980030)

  • 21. Desmoplastic melanoma with sarcomatoid dedifferentiation.
    Kiuru M; McDermott G; Berger M; Halpern AC; Busam KJ
    Am J Surg Pathol; 2014 Jun; 38(6):864-70. PubMed ID: 24618614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Desmoplastic melanoma: a challenge for the oncologist.
    Manfredini M; Pellacani G; Losi L; Maccaferri M; Tomasi A; Ponti G
    Future Oncol; 2017 Feb; 13(4):337-345. PubMed ID: 27728982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel diagnostic method to detect truncated neurofibromin in neurofibromatosis 1.
    Esposito T; Piluso G; Saracino D; Uccello R; Schettino C; Dato C; Capaldo G; Giugliano T; Varriale B; Paolisso G; Di Iorio G; Melone MA
    J Neurochem; 2015 Dec; 135(6):1123-8. PubMed ID: 26478990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.
    Agaimy A; Specht K; Stoehr R; Lorey T; Märkl B; Niedobitek G; Straub M; Hager T; Reis AC; Schilling B; Schneider-Stock R; Hartmann A; Mentzel T
    Am J Surg Pathol; 2016 Feb; 40(2):181-91. PubMed ID: 26448190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The RET G691S polymorphism is a germline variant in desmoplastic malignant melanoma.
    Barr J; Amato CM; Robinson SE; Kounalakis N; Robinson WA
    Melanoma Res; 2012 Feb; 22(1):92-5. PubMed ID: 22189301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relevance of BRAF Subcellular Localization and Its Interaction with
    Beleaua MA; Jung I; Braicu C; Milutin D; Gurzu S
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differing biologic behaviors of desmoplastic melanoma subtypes: Insights based on histopathologic, immunohistochemical, and genetic analyses.
    Yang K; Mahalingam M
    J Am Acad Dermatol; 2020 Aug; 83(2):523-531. PubMed ID: 32068045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.
    Jurkowska M; Gos A; Ptaszyński K; Michej W; Tysarowski A; Zub R; Siedlecki JA; Rutkowski P
    Int J Clin Exp Pathol; 2015; 8(7):8487-93. PubMed ID: 26339422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF mutation testing in melanoma: results from a German observational multicenter study.
    Hartmann A; Schirmacher P; Sterlacci W; Koch W; Liesenfeld DB; Schif B; Garbe C
    Virchows Arch; 2019 Jan; 474(1):71-78. PubMed ID: 30406424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma.
    Feller JK; Yang S; Mahalingam M
    Mod Pathol; 2013 Mar; 26(3):414-20. PubMed ID: 23041829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
    Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
    Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
    Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of SDHD promoter mutations in various types of melanoma.
    Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
    Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
    Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
    Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status.
    Mitchell B; Leone D; Feller JK; Bondzie P; Yang S; Park HY; Mahalingam M
    Melanoma Res; 2014 Dec; 24(6):621-5. PubMed ID: 25211166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.
    Ashida A; Uhara H; Mikoshiba A; Sakaizawa K; Kumagai N; Koga H; Okuyama R
    Acta Derm Venereol; 2016 Jan; 96(1):128-9. PubMed ID: 26123241
    [No Abstract]   [Full Text] [Related]  

  • 38. Lack of distinct molecular profile of Primary Dermal Melanoma.
    Shaigany S; Tessier-Cloutier B; Busam KJ; Horst BA
    Hum Pathol; 2020 Dec; 106():32-38. PubMed ID: 32946880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF V600E mutation-specific antibody: A review.
    Ritterhouse LL; Barletta JA
    Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.